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OBJECTIVES The aim of this study was to investigate whether endothelin-1, acting locally, regulates arterial
distensibility, assessed by measuring pulse-wave velocity in vivo.
BACKGROUND Arterial stiffness is a key determinant of cardiovascular risk. Several lines of evidence support
a role for the endothelium in regulating arterial stiffness by release of vasoactive mediators.
However, the role of endothelin-1 (ET-1) in the regulation of arterial stiffness has not been
investigated.
METHODS All studies were conducted in anesthetized sheep. Pulse wave velocity (PWV) was calculated
using the foot-to-foot methodology from two pressure waveforms simultaneously recorded
with a high-fidelity, dual pressure-sensing catheter placed in the common iliac artery.
RESULTS Intra-arterial infusion of ET-1 significantly increased iliac PWV by 12  5% (mean  STD;
p  0.001), whereas infusion of the endothelin-A (ETA) receptor antagonist BQ-123
significantly reduced PWV by 12  4% (p  0.001). After BQ-123 infusion, exogenously
infused ET-1 did not significantly change PWV compared with infusion of saline (change of
0.08  0.11% vs. 0.01  0.07%; p  0.53). Importantly, infusion of BQ-123 or ET-1
distal to the common iliac artery did not affect PWV.
CONCLUSIONS These results demonstrate, for the first time, that endogenous ET-1 production directly
regulates large artery PWV in vivo. In addition, exogenous ET-1 increases PWV, and this can
be blunted by ETA receptor blockade. These observations explain, in part, why conditions
that exhibit up-regulation of ET-1 are also associated with arterial stiffening. Therefore,
drugs that block ETA receptors may be effective in reducing large artery stiffness in humans,
and thus cardiovascular risk. (J Am Coll Cardiol 2003;42:1975–81) © 2003 by the
American College of Cardiology Foundation
Arterial stiffness is a key independent determinant of
cardiovascular risk (1,2). Structural components within the
arterial wall, mainly collagen and elastin, together with
transmural pressure are important determinants of large
vessel stiffness (3,4). However, smooth muscle tone can also
influence the stiffness of the elastic and muscular arteries
(5), suggesting there is also functional regulation of arterial
stiffness in vivo.
Nitric oxide (NO) and endothelin-1 (ET-1) are two
important mediators released by the vascular endothelium,
which exert major, but opposing influences on blood pres-
sure (6,7) and basal vascular tone (8,9). We have recently
shown that NO regulates large artery distensibility in vivo
(10), and this may explain why conditions that are charac-
terized by reduced NO bioavailability are also associated
with increased arterial stiffness. However, the role of ET-1
in the regulation of arterial stiffness is, at present, unclear.
Endothelin-1 exerts its actions on vascular smooth mus-
cle by binding to at least two specific receptor subtypes. The
endothelin-A (ETA) receptor is highly expressed on vascular
smooth muscle cells and appears to be the major receptor
subtype causing vasoconstriction in human (11) and ovine (12)
arteries. In contrast, the endothelin-B (ETB) receptor is
expressed on vascular smooth muscle cells mediating vasocon-
striction, and also on endothelial cells producing vasodilation
via the release of NO and prostacyclin (13). Local ETA
receptor blockade causes vasodilation of epicardial vessels
(14,15), demonstrating basal tone of ET-1 in larger arteries.
Moreover, arterial plasma ET-1 levels are positively correlated
with large artery stiffness in patients with coronary artery
disease (16). However, ET-1 is largely secreted abluminally by
endothelial cells toward the adjacent vascular smooth muscle
(17); thus, plasma ET-1 levels are a poor marker of its vascular
activity in vivo. Therefore, there are no direct data concerning
the role of ET-1 in regulating large artery stiffness.
We hypothesized that basal release of ET-1 contributes
to the regulation of large artery stiffness. The aim of this
study was to test this hypothesis in vivo in an anesthetized
ovine hind-limb preparation using intravascular measure-
ment of the pulse wave velocity (PWV) as a well-validated
index of arterial distensibility.
METHODS
All experiments were conducted in adult, crossbred Suffolk
sheep aged between 12 and 18 months, at the University of
From the *Clinical Pharmacology Unit, University of Cambridge, Addenbrooke’s
Hospital, Cambridge, United Kingdom; †Graduate School of Biomedical Engineer-
ing, University of New South Wales, Sydney, Australia; and ‡Department of
Cardiology, Wales Heart Research Institute, Cardiff, United Kingdom. Dr. Wilkin-
son, Dr. McEniery, and Prof. Cockcroft are supported by the British Heart
Foundation.
Manuscript received October 18, 2002; revised manuscript received May 19, 2003,
accepted June 3, 2003.
Journal of the American College of Cardiology Vol. 42, No. 11, 2003
© 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2003.06.016
New South Wales, Australia. The study was approved by
the University’s Animal Care and Ethics Committee. An-
esthesia was induced by intravenous injection of 600 to
900 mg sodium phenobarbitone (Rhone Merrieux, Queens-
land, Australia), and maintained by inhalation of 2% to 3%
halothane, administered through a Boyle’s rebreathing ap-
paratus with an oxygen flow rate of 2 l/min. Animals were
spontaneously breathing throughout and studied in the
supine position.
Hemodynamic measurements. All pressure measure-
ments were made using a Gaeltec 6F end-hole catheter
(Gaeltec, Skye, United Kingdom) with a 0.46-mm internal
lumen, and dual high-fidelity pressure sensors located 10
and 60 mm from the distal end. Calibration of both sensors
was performed simultaneously at the start of each experi-
ment using a mercury sphygmomanometer. The analogue
signal from the pressure control unit was fed directly into a
portable microcomputer using a PowerLab analogue-to-
digital converter (AD Instruments, Hastings, United King-
dom) with a sampling rate of 1 kHz. Data were recorded
over 20 s to allow for variations within the respiratory cycle.
Mean arterial pressure (MAP) was calculated from integra-
tion of the distal pressure waveform using the supplied
CHART software (Version 4). Data were then exported
and resampled at 10 kHz for further analysis with a
custom-written MATLAB analysis program (Math Works,
Cambridge, United Kingdom). This identifies the foot of
each of the simultaneously recorded pressure waveforms and
calculates the transit time (TT) from the foot-to-foot delay,
as previously described (10). The minimum resolution of
the system was a TT difference of 0.1 ms. The iliac PWV
was calculated as the fixed distance between the recording
sites (50 mm) divided by the TT, and it is inversely related
to arterial distensibility by the 1922 equation of Bramwell
and Hill (18):
PWV  [V  P/  V] [1]
where V  artery volume, V  change in volume, P 
change in pressure, and   blood density (assumed to be
constant in the present studies). For a distance of 50 mm,
the 0.1-ms resolution in TT provides a PWV resolution of
0.025 m/s (assuming a mean TT of 14 m/s). That is, PWV
can be estimated to within 0.7%. The repeatability of
measurements has been previously reported (10). Heart rate
(HR) was calculated over the measurement period from a
simultaneously recorded electrocardiogram.
Drugs. All drugs were freshly prepared in an aseptic
manner before the start of each experiment, using 0.9%
saline as a diluent. The ETA receptor antagonist, BQ-123
(Bachem, Bubendorf, Switzerland) was infused for 15 min
at 40 nmol/min, followed by saline. Endothelin-1 (Calbio-
chem, Nottingham, United Kingdom) was infused contin-
uously for 60 min at 10 pmol/min. These doses and
duration of infusions were based on published data (15,19)
and on our previous findings that doses active in the ovine
iliac artery are approximately equivalent to those used in
human forearm blood flow studies in vivo (10). In particular,
the regimen of BQ-123 infusion followed by saline was
based on previous data in the human forearm vascular bed,
demonstrating slow-onset dilation in response to BQ-123,
which persisted for 30 to 60 min following the end of the
infusion (20). Nevertheless, we performed pilot studies (data
not shown) with BQ-123 (10 to 100 nmol/min) and ET-1
(10 pmol/min) to confirm the choice of selected doses and
duration of infusions. The NO synthase inhibitor, NG-
monomethyl-L-arginine (LNMMA) (Clinalfa, Laufelfin-
gen, Switzerland) was infused at 10 mol/min and nor-
adrenaline (NA) (Abbott, Maidenhead, United Kingdom)
was infused at 600 pmol/min. The dose of LNMMA was
based on our previous data (10) and the dose of NA was
selected from pilot experiments (data not shown), to pro-
duce a similar baseline change in PWV as LNMMA
(6%).
Protocol. The distal femoral artery was identified by pal-
pation and a 20-mm segment of artery exposed by limited
dissection into which a 6F sheath was inserted. The arterial
catheter was then positioned in the common iliac artery, as
described previously (10). Saline was infused through the
sheath and catheter at 2 ml/min for a period of 30 min to
allow stabilization of the preparation. Baseline measure-
ments of iliac PWV, MAP, and HR were then recorded in
triplicate, or until measurements were stable (within 3% of
each other). All drugs were infused at 2 ml/min, and
pressure waveforms were recorded for 20 s, at 15-min
intervals during each infusion period. Infusion of drugs
through the catheter exposed the arterial segment under
study to the drug, whereas infusion through the sheath did
not, as this was located distally to the pressure sensors
(Fig. 1). Because the common iliac artery is nonbranching,
this methodology, which has been described previously (10),
allows indirect drug effects, such as those produced by
changes in flow or reflex activation, to be taken into account
by comparing the effect of infusion via the catheter with
infusion via the sheath.
EFFECT OF EXOGENOUS ET-1. Because of the slow onset
and prolonged action of ET-1, it was not possible to
administer ET-1 via both the sheath and catheter in the
same animal. Therefore, after baseline recordings had been
obtained, ET-1 (10 pmol/min) was infused through the
Abbreviations and Acronyms
ETA  endothelin-A
ET-1  endothelin-1
HR  heart rate
LNMMA  NG-monomethyl-L-arginine
MAP  mean arterial pressure
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NO  nitric oxide
PWV  pulse wave velocity
TT  transit time
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sheath in six sheep. In a further six sheep, ET-1 was infused
at the same dose through the catheter, followed by saline for
2 h to determine the offset of effect of ET-1 (Fig. 2A).
EFFECT OF ETA RECEPTOR BLOCKADE WITH BQ-123. Eight
sheep were studied. After baseline recordings had been
obtained, BQ-123 (40 nmol/min) was infused through the
sheath for 15 min followed by saline for 15 min. The
BQ-123 was then infused through the catheter for 15 min
followed by saline for 30 min. In four of the sheep, saline
was then infused for a further 45 min, and in the remaining
four animals, ET-1 was infused for 45 min, in place of saline
(both infusions were via the catheter; Fig. 2B).
In an additional control experiment, four sheep received
BQ-123 (40 nmol/min), via the sheath only, for 30 min
followed by saline for 30 min. This dose and the infusion
times of BQ-123 were equal to that infused in the previous
experiment (i.e., 15 min via the sheath plus 15 min via the
catheter, at 40 nmol/min). This control experiment was
conducted to exclude the possibility that any effects observed
in the previous experiment could be explained by “cumula-
tive dosing” or delayed onset of BQ-123, rather than a local
effect on the arterial wall.
Finally, to examine the role of NO on the observed
changes in PWV during ETA receptor blockade, BQ-123
(40 nmol/min for 15 min, followed by saline for 30 min)
was coinfused with either the NO synthase inhibitor,
LNMMA (10 mol/min; n 4), or the control constrictor,
NA (600 pmol/min; n  4).
Data analysis. All results are expressed as means  SD,
unless otherwise stated, and data corresponding to the
greatest change from baseline values are reported in the text.
Data were analyzed using repeated-measures analysis of
variance (ANOVA), and the Bonferroni test for post hoc
comparisons, where appropriate. A p value of  0.05 was
considered significant.
RESULTS
Effect of exogenous ET-1 on PWV. Infusion of ET-1 via
the sheath did not change iliac PWV (3.95  0.46 vs. 3.92
 0.28 m/s; p  0.6) or MAP (106  12 vs. 109  10 mm
Hg; p 0.2), but there was a significant decline in HR (7
 4 beats/min; Table 1). However, there was a gradual and
significant increase in iliac PWV of 12  5%, when ET-1
was infused through the catheter (3.54  0.54 vs. 3.98 
0.64 m/s after 60 min; p  0.001; Fig. 3), which had
returned to baseline (3.65 0.3 m/s; p 0.97) 60 min after
stopping the ET-1 infusion.
Effect of BQ-123 on PWV. Eight sheep received intra-
arterial BQ-123. There was no change in iliac PWV when
BQ-123 was infused via the femoral artery sheath (3.59 
0.32 vs. 3.52  0.27 m/s; p  0.2). However, there was a
significant and gradual decrease in the PWV of 12  4%
following infusion through the catheter (3.52  0.27 vs.
3.16  0.25 m/s after 45 min; p  0.001; Fig. 4). Mean
arterial pressure was significantly reduced following infusion
of BQ-123 both through the sheath (change of4 4 mm
Hg; p  0.02) and through the catheter (change of 6 
4 mm Hg; p  0.001). However, the magnitude of this
change did not differ significantly between the two routes
(p  0.87; Table 2). No change occurred in HR.
Administration of ET-1 or saline through the catheter,
Figure 1. Schema showing drug infusions via the catheter (proximal) and sheath (distal). P1  pressure sensor 1; P2  pressure sensor 2.
Figure 2. Experimental protocol. (A) Infusion of exogenous endothelin-1
(ET-1); (B) infusion of BQ-123.
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after infusion of BQ-123, did not significantly alter PWV
(3.16  0.25 vs. 3.08  0.22 m/s; p  0.53; and 3.16 
0.25 vs. 3.12  0.26 m/s; p  0.06, respectively; Fig. 4).
Doubling the duration of BQ-123 infusion via the sheath
in four sheep (40 nmol/min for 30 min), to provide the same
cumulative dose as given in the first series of experiments,
did not alter PWV (change of 2  3%; p  0.58), despite
producing exactly the same average change in MAP (6 
2 mm Hg; p 0.01; p 0.41 for comparison). Once again,
no change occurred in HR.
Co-infusion of BQ-123 and LNMMA produced a sig-
nificant reduction in PWV (change of9 3%; p 0.04),
which was similar to that observed when BQ-123 was
co-infused with NA, as a control constrictor for LNMMA
(change of 8  6%; p  0.04; p  0.32 for comparison).
DISCUSSION
Large artery stiffness is a powerful and independent predic-
tor of cardiovascular risk (1,2). Smooth muscle tone influ-
ences the stiffness of the elastic and muscular arteries (5),
and removal of the vascular endothelium modifies large
artery mechanics in vivo (21,22), suggesting a degree of
functional regulation of large artery stiffness by
endothelium-derived vasoactive mediators. Indeed, we and
others have recently shown that NO regulates large artery
distensibility (10,23). Such observations may explain why a
number of conditions associated with increased large artery
stiffness, such as hypertension and hypercholesterolemia, are
also associated with endothelial dysfunction, through either
reduced bioavailability of NO (24,25) or enhanced vascular
activity of endothelium-derived vasoconstrictors such as
ET-1 (26,27).
In the current study, we extend our previous findings by
demonstrating, for the first time, that selective blockade of
ETA receptors with BQ-123 substantially reduces PWV in
the ovine iliac artery. We have also shown that infusion of
exogenous ET-1 increases PWV in the ovine iliac artery,
and that infusion of an ETA receptor antagonist signifi-
cantly attenuates this effect. Together, these data suggest
that endogenous ET-1, acting via the ETA receptor, regu-
lates arterial distensibility in vivo.
Effect of exogenous ET-1 on PWV. A comparison of the
effect of ET-1 infused via the sheath and catheter on PWV
provided information concerning the effects of exogenous
ET-1–mediated stimulation of endothelin receptors, while
controlling for any reflex or hemodynamic changes associ-
ated with the ET-1 infusion. Indeed, distal infusion of
ET-1 did not alter PWV in the iliac artery, or cause any
change in MAP. However, a gradual and significant in-
crease occurred in the iliac PWV of 12% after 60 min,
when the same dose of ET-1 was infused through the
catheter. This effect of ET-1 is similar to the slow-onset
effect observed previously in isolated vessel studies in vitro
(28) and in the human forearm vascular bed in vivo (9). The
increase in PWV was not accompanied by any systemic
Table 1. Effect of ET-1 on Hemodynamics
Sheath Catheter
Baseline ET-1 Baseline ET-1
Iliac PWV, m/s 3.95  0.46 3.92  0.28 3.54  0.54 3.98  0.64†‡
MAP, mm Hg 106  12 109  10 110  11 110  10
HR, beats/min 148  17 141  16* 126  18 125  15
Values are means  SD. *p  0.05. †p  0.01, compared with baseline values. ‡p  0.001, for change compared with saline
infusion via sheath.
ET-1  endothelin-1; HR  heart rate; MAP  mean arterial pressure; PWV  pulse wave velocity.
Figure 3. The effect of intra-arterial infusion of endothelin-1 (ET-1) via
the catheter on iliac pulse wave velocity (PWV) (n  6). Values represent
means  SD; p  0.001 (ANOVA), compared with saline. *p  0.01.
**p  0.001, Bonferroni test.
Figure 4. The effect of intra-arterial infusion of BQ-123 through the
sheath and catheter (triangles, n  8), followed by endothelin-1 (ET-1)
(open squares, n 4), or saline (closed squares, n 4) on iliac pulse wave
velocity (PWV). Values represent means  SD; p  0.001 (ANOVA),
compared with saline. *p  0.001, Bonferroni test.
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hemodynamic changes, indicating that the response to
exogenous ET-1 was due to a direct action on the local
arterial wall, and not the result of potentially confounding
changes in systemic MAP. These data thus suggest that
infusion of exogenous ET-1 decreases local arterial disten-
sibility in vivo.
Effect of BQ-123 on PWV. Infusion of the selective ETA
receptor antagonist BQ-123 via the catheter resulted in a
significant decrease in PWV, suggesting an increase in
arterial distensibility. The time-course of this effect of
BQ-123 (slow-onset and persistent for up to 30 min after
stopping the infusion) was similar to responses in the
human forearm vascular bed in vivo (20). Although the
decrease in PWV was accompanied by a small but signifi-
cant reduction in MAP (6 mm Hg), previous data relating
MAP to PWV suggest that such a change will alter PWV
by 3% (29). Moreover, a blood pressure–independent
effect of BQ-123 on PWV in the present study is supported
by the observation that when BQ-123 was infused via the
sheath at either the same, or twice, the dose as given
through the catheter, there was no change in the PWV
despite reductions in MAP of 4 mm Hg and 6 mm Hg,
respectively (NS for both comparisons vs. change via the
catheter). Taken together, these data indicate that the
majority of the effect of BQ-123 on PWV in the present
study is due to a direct action on the arterial wall rather than
a drop in MAP, suggesting, for the first time, that blockade
of endogenous ET-1–mediated vasoconstriction via the
ETA receptor increases large artery distensibility in vivo.
Infusion of BQ-123 abolished the effect of exogenous
ET-1 on PWV, indicating that the effect of endogenous
ET-1 on PWV is, to a large extent, mediated via the ETA
receptor. Interestingly, when BQ-123 was co-infused with
the NO synthase inhibitor LNMMA, the PWV fell by
9%, which, although less than that observed in the
previous experiment, when BQ-123 was infused alone
(12%), was similar to that observed when BQ-123 was
co-infused with the control constrictor NA (8%). There-
fore, it is unlikely that increased NO production, via
unopposed ETB receptor stimulation (for example), is
responsible for the observed effect of BQ-123 in the current
series of experiments. This is in contrast with data from
human studies in vivo, which suggest that NO does contrib-
ute to the vascular responses during ETA receptor blockade
(30,31), most probably via increased stimulation of ETB
receptors by ET-1. However, a role for ETB receptors in the
functional regulation of arterial distensibility in the current
investigation cannot be fully excluded, because ETB recep-
tors also act to release other vasoactive mediators such as
prostacyclin (13). Therefore, further work is now required to
examine the role of ETB receptors in regulating arterial
distensibility.
Physiological importance of ET-1. The physiological im-
portance of endogenous ET-1 to basal vascular tone in
resistance vessels has been demonstrated in vivo by vasodi-
lation in response to both local (9,20) and systemic (7) ETA
receptor blockade. Moreover, local ETA receptor blockade
causes vasodilation of epicardial vessels (14,15), demonstrat-
ing basal tone of ET-1 in larger arteries. The current
findings add to these data by demonstrating a pronounced
effect of ETA receptor blockade in a large muscular artery.
Furthermore, it appears that ET-1 may be more important
to the regulation of large artery stiffness than NO. The ETA
receptor blockade with BQ-123 reduced PWV by 12%.
This effect appears greater than the changes we observed
during inhibition of basal NO production in the same
experimental setting, although in different animals, when
PWV increased by only 3% (10). However, these findings
are consistent with data from human in vivo studies, where
infusion of BQ-123 increases forearm blood flow by 60%
(9,20) whereas LNMMA reduces forearm blood flow by
only 40% (8,32). In humans, femoral PWV increases by
5.5% for each decade of life (3). Therefore, if BQ-123 has
an effect on PWV in humans similar to that in the ovine
iliac artery, inhibition of the ETA receptor-mediated actions
of endogenous ET-1 would effectively reduce large artery
stiffness by 15 years. Thus, an increased vasoconstrictor
activity of ET-1 may, in part, explain the association
between premature arterial stiffening and established car-
diovascular risk factors such as hypercholesterolemia (33,34)
and cigarette smoking (35). Hence, it may be possible to
reduce arterial stiffness pharmacologically through drug
therapies targeted at reducing vasoconstriction to ET-1.
Such therapies, aimed at the large arteries, may reduce the
burden of morbidity and mortality from cardiovascular
disease.
Potential considerations. The present study used the
ovine iliac artery as a model of large arteries in humans.
Therefore, the applicability of the results to humans requires
confirmation. However, as in humans, ET-1 exerts potent
Table 2. Effect of BQ-123 on Hemodynamics
Sheath Catheter
Saline
(30 min)
BQ-123
(45 min)
Saline
(60 min)
BQ-123
(75 min)
Saline
(90 min)
Saline
(105 min)
Iliac PWV, m/s 3.59  0.32 3.54  0.29 3.52  0.29 3.25  0.29 3.27  0.31 3.16  0.25†‡
MAP, mm Hg 106  17 103  17 102  18* 100  19 98  18 96  19*
HR, beats/min 128  17 128  18 127  16 127  12 121  13 124  16
Values shown in parentheses refer to the number of minutes following commencement of study. Values obtained during the final saline infusion via the sheath (60 min) were
used as the baseline for infusions via the catheter. All values are means SD. *p 0.05. †p 0.01, compared with baseline values. ‡p 0.001, for change compared with infusion
via the sheath.
Abbreviations as in Table 1.
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cardiovascular actions in sheep (36), which can be antago-
nized with BQ-123 (37). In particular, the ovine and human
responses to systemic infusion of ET-1 (36,38) and ETA
receptor blockade (7,37) are similar. In addition, inhibition
of basal NO production with LNMMA has a similar effect
on arterial distensibility in the ovine iliac artery (10), and on
human brachial artery (23) in vivo.
The use of general anesthesia may have influenced our
results to some degree. However, owing to the need to make
very high fidelity recordings, it was not possible to use
conscious animals. Nevertheless, we believe that the ovine
hind-limb preparation is a useful surrogate model for the
effects of drugs and vasoactive mediators in large muscular
artery mechanics.
Although the dose regimen of BQ-123 used in the
present study has been described previously (15), we may
have underestimated the maximal effect of BQ-123. More-
over, the precise mechanisms underlying the observed
changes in PWV in response to drug infusions remain
unclear, because we did not measure artery diameter. Al-
though PWV is a measure of distensibility, factors influ-
encing distensibility include vessel diameter, wall thickness,
and wall stiffness, possibly due to altered relative loading of
elastin and collagen fibers within the arterial wall, accom-
panying changes in smooth muscle tone. Therefore, we are
unable to identify which parameters are responsible for the
observed changes in PWV in the present investigation.
However, it would seem unlikely that alterations in vascular
resistance in the hind-limb is responsible for the changes in
PWV because infusion of ET-1 and BQ-123 via the sheath
had no effect. Similarly, a delayed effect of BQ-123 on
resistance vessels is unlikely because when BQ-123 was
infused via the sheath for twice as long (i.e., 30 min) and
then followed by saline for 30 min, there was no change in
the PWV despite a similar reduction in MAP to that
observed during other infusions.
A potential limitation in our study design is that although
we demonstrated that the effect of exogenous ET-1 on
PWV was abolished following BQ-123 infusion, we did not
infuse a comparator vasoconstrictor to ensure that a change
in baseline did not account for the lack of effect of ET-1
post–BQ-123. However, such an approach was not feasible
owing to concerns about the duration of the experiments
(both ethical and relating to preparation stability).
Finally, the role of the ETB receptor was not examined in
the current study. Although our findings suggest that NO
does not appear to play a major role in the regulation of
arterial distensibility during ETA receptor blockade, endo-
thelial ETB receptors release other vasoactive mediators
such as prostacyclin (13), which may also be important in
the functional regulation of large artery distensibility.
Therefore, further studies using ETB antagonists are re-
quired to examine the role of ETB receptors, and to more
fully characterize the effects of endogenous ET-1 in regu-
lating large artery distensibility.
Summary. We have demonstrated, for the first time, that
endogenous ET-1, acting via the ETA receptor, regulates
large artery distensibility, assessed by measuring PWV in
vivo. Such findings confirm and extend our previous obser-
vations that there is functional regulation of arterial disten-
sibility, mediated, in part, by locally generated vasoactive
factors. Therefore, an increased vascular activity of ET-1
may help to explain the association between established
cardiovascular risk factors and premature arterial stiffening.
Drugs that block ETA receptors may be effective in reducing
large artery stiffness in humans, and thus cardiovascular risk.
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